NL-OMON46723已完成不适用
A 2-Part, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Subjects - JNJ-55375515 SAD study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male subject between 18 and 54 years of age, inclusive.
- •Body Mass Index (BMI) between 18 and 30 kg/m2 inclusive
- •Non-smoker (not smoked for 3 months prior to screening)
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A 2-Part Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer*s DiseaseNL-OMON48645Janssen-Cilag36
招募中
3 期
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)JPRN-jRCT2071210048Okawa Yasutoshi25
进行中（未招募）
1 期
Global Linerixibat Itch STudy of Efficacy and Safety iN PBC (GLISTEN)EUCTR2021-000007-21-BEGlaxoSmithKline Research & Development Limited230
进行中（未招募）
1 期
Global Linerixibat Itch STudy of Efficacy and Safety iN PBC (GLISTEN)EUCTR2021-000007-21-CZGlaxoSmithKline Research & Development Limited230
进行中（未招募）
1 期
Global Linerixibat Itch STudy of Efficacy and Safety iN PBC (GLISTEN)EUCTR2021-000007-21-ITGLAXOSMITHKLINE RESEARCH AND DEVELOPMENT230